temozolomide has been researched along with Kidney Failure, Chronic in 1 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide was successfully up-titrated to the full dose." | 1.91 | Safe administration of temozolomide in end-stage renal disease patients. ( Hundal, J; Pereira, MK; Singh, A; Vredenburg, J, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hundal, J | 3 |
| Singh, A | 3 |
| Pereira, MK | 3 |
| Vredenburg, J | 3 |
1 other study available for temozolomide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |